ClinicalTrials.gg
CompletedNCT03722147Updated Apr 3, 2024

A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma

A Phase 1/2 interventional study of AK105 in Hodgkin's Lymphoma, sponsored by Akeso. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-03.

Sponsored by Akeso · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2020, 6 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
94
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 56 studies in Hodgkin Disease with a site in China — 27 open to participants now, 30 under way, 3 of them phase 3. Hodgkin Disease · China.

Enrollment
22nd of 53
94 · median 75
Started
2018
with 4 others
Phase 1/2
10 of 56
5 open now
Registered
17th of 56
by date
Lead sponsor
3 of 56
Akeso

Among the 56 studies in Hodgkin Disease with a site in China, this one is the 22nd largest by enrollment of the 53 interventional ones that give a count, is one of 5 that started in 2018, is one of 10 in phase 1/2, and was the 17th registered.

Hodgkin Disease

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

27 of the 56 studies in Hodgkin Disease with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Hodgkin Disease with a site in China, or all of them as a file.
02

Study summary

This is a single-arm, open-label, multicenter, phase I/II study to evaluate efficacy and safety of AK105 in patients with relapsed or refractory classic Hodgkin lymphoma.

03

Conditions studied

  • Hodgkin's Lymphoma

Browse trials for

Keywords

  • immunotherapy
  • immuno-oncology
  • Classic Hodgkin Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written and signed
  2. (ECOG) Performance Score of 0 or 1
  3. confirmed classic Hodgkin's lymphoma (cHL) (based on tumor tissue obtained within 3 years prior to enrollment).
  4. (disease progression during or after most recent therapy) or refractory (failure to achieve CR or PR after most recent therapy) cHL and meet any of the following criterions:

    1. Recurrence or disease progression after hematopoietic stem cell transplantation.
    2. For subject without receiving , the subject has received at least 2 lines of prior systemic chemotherapy. Refractory subject is defined as subject who has not achieved PR after at least 2 cycles of treatment, or subject who has not achieved CR after at least 4 cycles of treatment. If the best response to treatment is PD or the reason for ending the treatment is PD, the subject is consider as refractory without requirement on the number of cycles of treatment that the subject has received. For relapsed subjects, disease progression occurred for the subject who has received at least 2 line of prior systemic chemotherapy.
  5. Subject must have at least one (> 1.5 cm in the longest diameter, or > 1 cm in the longest diameter with uptake on 18FDG-PET)according to the Lugano 2014 criteria.
  6. Adequate organ functions.
  7. Use effective methods of .

Exclusion criteria

Exclusion Criteria:

  1. Known nodular lymphoma predominant Hodgkin lymphoma or Grey zone lymphoma.
  2. Lymphoma involving the central nervous system.
  3. Participated in other clinical studies of experimental drugs or received research treatment or used experimental equipment within 4 weeks prior to the first dose of AK105.
  4. Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study.
  5. Receipt of the last radiotherapy or the last dose of anticancer therapy (chemotherapy, target therapy, immunotherapy or tumor embolism, etc.) with 4 weeks prior to the first dose of AK105. Receipt of the last dose of nitrocarbamide or mitomycin C within 6 weeks prior to the first dose of AK105.
  6. Prior exposure to any , anti-PD-L1, anti-CTL4 antibody or any other antibody or drug targeting T-cell costimulation or checkpoint pathways such as ICOS, or agonists such as 0, CD137, GITR, OX40 etc..
  7. Had other active within 5 years prior to enrollment. Locally curable cancer (manifested as cured) is excluded, such as basal or cutaneous squamous cell carcinoma, superficial bladder cancer, cervical or breast carcinoma in situ.
  8. Active, known or suspected diseases, or a history of the disease within the past 2 years, except the following: vitiligo, alopecia, Graves' disease, psoriasis or eczema that do not require systemic treatment within the last 2 years, hypothyroidism (caused by autoimmune thyroiditis) only requiring a stable dose of hormone replacement therapy, type I diabetes requiring only a stable dose of insulin replacement therapy, or diseases not expected to recur in the absence of external triggering factors.
  9. Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis or chronic diarrhea).
  10. Subjects with a condition requiring systemic treatment with either (> 10 mg daily prednisone equivalents) or other medications within 14 days of study drug administration.
  11. History of testing positive for (HIV) or known acquired immunodeficiency syndrome (AIDS).
  12. History of primary immunodeficiency.
  13. History of active tuberculosis.
  14. History of stem cell transplantation or organ transplantation.
  15. Autologous hematopoietic stem cell transplantation performed within 90 days prior to the first dose of AK105.
  16. History of gastrointestinal perforation and /or within 6 months prior to enrollment.
  17. History of interstitial lung disease.
  18. Patients with untreated chronic or with HBV DNA exceeding 500 IU/mL, or with active should be excluded. Inactive HBsAg carriers, treated and stable hepatitis B patients (HBV DNA \< 500 IU/mL), or cured hepatitis C patients can be enrolled. For patients with positive HCV antibody, they are eligible to participate in the study only if the test result of HCV RNA is negative.
  19. Major surgical procedure (as defined by the investigator) within 30 days prior to the first dose of AK105 or still recovering from prior surgery. Local procedures (eg, placement of a systemic port, core needle , and prostate biopsy) are allowed if completed at least 24 hours prior to the administration of the first dose of study treatment.
  20. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
  21. Active infections requiring systemic treatment.
  22. Uncontrolled concurrent disease, including but not limited to, persistent or active infection, symptomatic congestive heart failure (according to the functional class defined 3 or 4), out of control of high blood pressure, unstable angina, arrhythmia, severe peptic ulcer or gastritis, activity, or mental illness/social status which will limit the participants compliance requirements or damage to the participants to provide written .
  23. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to National Cancer Institute's (NCI's) (CTCAE) (NCI CTCAE v4.03) Grade 0 or 1, or to levels dictated in the inclusion/exclusion criteria with the exception of alopecia. Subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the study drug may be included (eg, hearing loss) after consultation with the medical monitor. Subjects with ≤ Grade 2 neuropathy will be evaluated on a case-by-case basis after consultation with the medical monitor.
  24. Receipt of live or attenuated vaccination within 30 days prior to the first dose of AK105, or plan to have live or attenuated vaccination during the study.
  25. Known allergy or reaction to any component of the AK105 formulation.
  26. History of severe allergic reaction to any other monoclonal antibodies.
  27. Women who are pregnant or nursing.
  28. Any condition that, in the opinion of the investigator, would interfere with evaluation of the product or interpretation of subject safety or study results.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
94 participants (actual)

Study arms

  • Experimental
    AK105

    AK105 200 mg intravenously (IV) every-2-weeks (Q2W)

    Biological: AK105

Interventions

  • BiologicalAK105

    AK105 200 mg intravenously (IV) every-2-weeks (Q2W)

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR) assessed by Independent Radiology Review Committee (IRRC) per the Lugano 2014 Classification

    ORR defined as the proportion of subjects who achieves a best overall response of CR or PR, assessed by IRRC per the Lugano 2014 Classification.

    Time frame: Up to 2 years

  2. Number of subjects with adverse events (AEs)

    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: From the time of informed consent signed through 90 days after the last dose of AK105

Secondary outcomes

  1. ORR assessed by Investigator

    ORR defined as the proportion of subjects who achieves a best overall response of CR or PR, assessed by Investigator per the Lugano 2014 Classification.

    Time frame: Up to 2 years

  2. Duration of Response (DoR)

    From the date that CR or PR are first occurred to the date of objective disease progression or death, whichever occurs first.

    Time frame: Up to 2 years

  3. Progression-free Survival (PFS)

    From the first dose of AK105 to the date of the date of objective disease progression or death, whichever occurs first.

    Time frame: Up to 2 years

  4. Disease control rate (DCR)

    DCR defined as the proportion of subjects response of CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD for ≥8 weeks) per the Lugano 2014 Classification.

    Time frame: Up to 2 years

  5. Minimum observed concentration (Cmin) of AK105 at steady state

    The endpoints for assessment of PK of AK105 include serum concentrations of AK105 at different timepoints after AK105 administration.

    Time frame: From first dose of AK105 through 30 days after last dose of AK105

  6. Number of subjects who develop detectable anti-drug antibodies (ADAs)

    The immunogenicity of AK105 will be assessed by summarizing the number of subjects who develop detectable antidrug antibodies (ADAs).

    Time frame: From first dose of AK105 through to 90 days after last dose of AK105

07

Study locations

1 site
  • Beijing Cancer Hospital
    Beijing, Beiing 100142, China
08

References and documents

Publications

  • Huang Z, Pang X, Zhong T, Qu T, Chen N, Ma S, He X, Xia D, Wang M, Xia M, Li B. Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events. Front Immunol. 2022 Jun 27;13:924542. doi: 10.3389/fimmu.2022.924542. eCollection 2022. PubMed 35833116 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Jan 2020, 16 months.

Of 63 phase 1/2 interventional studies under Hodgkin Disease, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 53 and three quarters within 97. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2018
First posted
Oct 26, 2018
StartActual
Aug 13, 2018
Primary completionActual
Jan 10, 2020
CompletionActual
Dec 31, 2021
Last update
Apr 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03722147
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Oct 26, 2018
Start date
Aug 13, 2018
Primary completion
Jan 10, 2020
Completion
Dec 31, 2021
Last update
Apr 3, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Penpulimab

Start the discussion